Lung Carcinoma Metastatic to the Brain
Conditions
Keywords
MRI perfusion, therapeutic response, chemotherapy, brain metastases
Brief summary
This study therefore aims to assess current treatment recommended by scientific societies \[ 6-13 \] , brain MRI with injection of contrast for the diagnosis and monitoring of brain metastases . The recommended dose of this examination gadolinium is from 0.1 to 0.3 mmol / kg \[ 14 \] . Sequences infusion different from one center to the other made : some use the infusion T1, other infusion T2 \* . No recommendation establishes whether it is preferable to use one or the other of these sequences. No examination is added for the purposes of protocol. Indications for MRI and the number and timing of MRI checks under this protocol are consistent with what is done in practice . The used type of gadolinium and the injected dose will be identical for both sequences infusion . The assessment shall not in any case the contrast but the interpretation of the sequence itself. Special procedures monitoring implemented embodiment correspond to the two sequences instead of infusion (one of T1-weighted and T2 \* in the other ) , in the original MRI and MRI of the first control , in order to compare their effectiveness
Detailed description
Eligibility criteria: * Major Patients * Addressed MRI for initial assessment of brain metastases * At a suspicion of one or more brain metastases in the brain scanner routine screening * Follow for lung cancer histologically documented * In the Thoracic Oncology Service Professor Lafitte (contact: Dr Cortot) * To whom treatment with chemotherapy or targeted therapy (including anti-angiogenic) is considered * Be socially insured Main Outcomes measures: Comparing the area under the ROC curve of different parameters evaluated in T1 and T2 \* perfusion during the initial assessment for the diagnosis of maximal tumor response evaluated at 1 year
Interventions
OTHERMRI T1 T2 sequences
MRI
Sponsors
University Hospital, Lille
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Major Patients * Addressed to MRI for initial assessment of brain metastases * At a suspicion of one or more brain metastases in the brain scanner routine screening * Followed for lung cancer histologically documented in the Thoracic Oncology Service of Professor Lafitte (contact: Dr Cortot) * To whom treatment with chemotherapy or targeted therapy (including anti-angiogenic) is considered * Be socially insured-
Exclusion criteria
* Absolute contraindication to MRI (pacemaker, implantable pacemaker, metallic foreign body intraorbital) * Patients minors under guardianship / curatorship * Patients with impaired judgment skills or unable to receive information * Pregnant Women * Patients for which lesions are not compatible with lung metastases * Patients with brain metastases or already known and explored MRI * Patients for whom treatment by surgical excision of brain metastases is considered
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparing different parameters evaluated in T1 and T2 * perfusion | 3 years | Comparing the area under the ROC curve of different parameters evaluated in T1 and T2 \* perfusion during the initial assessment for the diagnosis of maximal tumor |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation tumor response | 1 year | Comparison of the area under the ROC curve of the change in the first control of the various parameters measured in T1 and T2 \* infusion, for the diagnosis of maximum tumor response evaluated at 1 year |
| Radiological progression-free survival | 1 year | Comparison of the ability of the two sequences to predict infusion: |
| Survival without neurological signs | 1 year | Comparison of the ability of the two sequences to predict infusion: |
Countries
France
Contacts
STUDY_DIRECTORXavier LECLERC, Professor
CHRU of Lille
Outcome results
None listed